Bendamustine: safety and efficacy in the management of indolent non-hodgkins lymphoma
about
An open-label expanded-access trial of bendamustine in patients with rituximab-refractory indolent non-Hodgkin lymphoma or previously untreated chronic lymphocytic leukemia: BEND-ACTSevere dermatologic reactions with bendamustine: a case series.Late Occurrence of PML in a Patient Treated for Lymphoma with Immunomodulatory Chemotherapies, Bendamustine, Rituximab, and Ibritumomab Tiuxetan.A Canadian perspective on bendamustine for the treatment of chronic lymphocytic leukemia and non-Hodgkin lymphomaA Canadian perspective on the safe administration of bendamustine and the prevention and management of adverse events.Investigation of bendamustine HCL in a phase 2 study in women with resistant ovarian cancer.Bendamustine-based therapy as first-line treatment for non-Hodgkin lymphoma.Results of a phase II study of bendamustine and ofatumumab in untreated indolent B cell non-Hodgkin's lymphoma.Bendamustine and its role in the treatment of unfit patients with chronic lymphocytic leukaemia: a perspective review.Bendamustine associated immune suppression and infections during therapy of hematological malignancies.The combination effects of bendamustine with antimetabolites against childhood acute lymphoblastic leukemia cells.Bendamustine-associated infections-systematic review and meta-analysis of randomized controlled trials.Infections associated with bendamustine containing regimens in hematological patients: a retrospective multi-center study.
P2860
Q33425372-30CE2B7B-7E6C-40FD-9435-38126E12EE97Q34023450-C40032A8-F5F3-4617-A286-3EB163BE9581Q35078693-505367B2-F287-48C8-AD88-7AD2556CBBF0Q36000197-976A9E6C-5E2C-490B-8023-A31FF9EC56B8Q37577645-F452ABB5-57C3-4C9A-B049-B6328DD11F2EQ37705010-D86B8BBA-49EC-4005-9C26-63E4007429B7Q38206120-1E2C316A-919F-4ECD-9145-0BF24F0458D5Q38417140-3D062053-78BB-4AE0-B379-E3E6205D5E0CQ38676408-6C2F036E-F7AF-41E7-BAFD-CDF17115720DQ38676858-0A53DA54-E85D-41EF-85AA-BF3D0445CCE1Q38793446-C56C1FA9-9718-4CD7-96D6-347FA92E633DQ38979354-8E7F313C-F25E-4B51-BF80-9AD0DD46ED7EQ41257177-850E5A13-0697-4104-A395-A16FADFD4486
P2860
Bendamustine: safety and efficacy in the management of indolent non-hodgkins lymphoma
description
2011 nî lūn-bûn
@nan
2011 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Bendamustine: safety and efficacy in the management of indolent non-hodgkins lymphoma
@ast
Bendamustine: safety and efficacy in the management of indolent non-hodgkins lymphoma
@en
type
label
Bendamustine: safety and efficacy in the management of indolent non-hodgkins lymphoma
@ast
Bendamustine: safety and efficacy in the management of indolent non-hodgkins lymphoma
@en
prefLabel
Bendamustine: safety and efficacy in the management of indolent non-hodgkins lymphoma
@ast
Bendamustine: safety and efficacy in the management of indolent non-hodgkins lymphoma
@en
P2860
P356
P1476
Bendamustine: safety and efficacy in the management of indolent non-hodgkins lymphoma
@en
P2093
Nishant Tageja
P2860
P304
P356
10.4137/CMO.S6085
P407
P577
2011-05-18T00:00:00Z